Eterna Therapeutics Inc is a biopharmaceutical company. The company develops transformational new medicines using advanced cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indicati... Eterna Therapeutics Inc is a biopharmaceutical company. The company develops transformational new medicines using advanced cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. With its strategic partners, the group is developing nucleic acid and cell therapies that can significantly improve the health outcomes of patients with high unmet medical needs. 詳細を表示
CAMBRIDGE, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA) today announced it will investigate the ability of its lead iMSC-based cell therapy (ERNA-101) to induce...
CAMBRIDGE, Mass., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics, Inc. (Nasdaq: ERNA), a leader in cell therapies, today announced that its Board of Directors has authorized a stock...
CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”) announced today that it has regained compliance with Nasdaq for continued...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0233 | -8.55673889093 | 0.2723 | 0.3 | 0.2212 | 405016 | 0.2540777 | CS |
4 | -0.2708 | -52.0969603694 | 0.5198 | 0.525 | 0.2212 | 2046832 | 0.31151618 | CS |
12 | -0.781 | -75.8252427184 | 1.03 | 1.25 | 0.2212 | 733087 | 0.35449906 | CS |
26 | -1.661 | -86.9633507853 | 1.91 | 2.625 | 0.2212 | 349754 | 0.38967784 | CS |
52 | -1.591 | -86.4673913043 | 1.84 | 2.625 | 0.2212 | 182839 | 0.42769562 | CS |
156 | -3.951 | -94.0714285714 | 4.2 | 7.15 | 0.2212 | 108810 | 1.23375634 | CS |
260 | -3.951 | -94.0714285714 | 4.2 | 7.15 | 0.2212 | 108810 | 1.23375634 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約